The Effectiveness of Add-on Treatment with Nutraceutical

Aim: evaluation of the effectiveness of the nutraceutical “Standard Zdorovia: Gastro” (“SZ Gastro”) in the treatment of patients with irritable bowel syndrome (IBS).

Materials and methods. 52 patients (62 % women) diagnosed with IBS and IBS in combination with functional dyspepsia (FD) were included in the study and divided into two groups. Both groups received basic therapy according to the guidelines. The experimental group received as add-on the nutraceutical “SZ Gastro” (containing a standardized amount of menthol, gingerol and D-limonene); patients in the control group — placebo. The duration of the study was 30 days. The severity of somatic symptoms was assessed with the 7×7 questionnaire. Emotional state was assessed with the Four Dimensional Distress, Depression, Anxiety, and Somatization Questionnaire (4DSQ).

Results. Patients of the experimental and control groups did not differ from each other either in terms of demographics, basic treatment, or in the severity of symptoms at the beginning of the study.

The effectiveness of the treatment in the patients, who received add-on “SZ Gastro” was significantly higher than in the patients of the control group: in the control group the percentage of improvement of somatic symptoms was 22.35 %, in the experimental group it amounted to 49.18 % (χ² = 15.9; p = 0.0001). The percentage of patients with significant decrease of emotional disturbances was also higher in the experimental group: distress (χ² = 18.7; p = 0.0000), anxiety (χ² = 6.9; p = 0.0097) and somatization (χ² = 14.99; p = 0.0001). No significant side effects were registered in any of the groups.

Conclusions. Add-on of nutraceutical “SZ Gastro” to basic treatment is safe and significantly increases effectiveness of the therapy in the patients with IBS and IBS in combination with PD.

1. Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., et al. Bowel Disorders. Gastroenterology. 2016:S0016-5085(16)00222-5. DOI: 10.1053/j.gastro.2016.02.031

2. Black C.J., Ford A.C. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473–86. DOI: 10.1038/s41575-020-0286-8

3. von Wulffen M., Talley N.J., Hammer J., McMaster J., Rich G., Shah A., et al. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci. 2019;64(2):480–6. DOI: 10.1007/s10620-018-5343-6

4. Lee C., Doo E., Choi J.M., Jang S.H., Ryu H.S., Lee J.Y., et al. The Increased Level of Depression and Anxiety in Irritable Bowel Syndrome Patients Compared with Healthy Controls: Systematic Review and Meta-analysis. J Neurogastroenterol Motil. 2017;23(3):349–62. DOI: 10.5056/jnm16220

5. Perveen I., Rahman M.M., Saha M., Rahman M.M., Hasan M.Q. Prevalence of irritable bowel syndrome and functional dyspepsia, overlapping symptoms, and associated factors in a general population of Bangladesh. Indian J Gastroenterol. 2014;33(3):265–73. DOI: 10.1007/s12664014-0447-1

6. Morozova M.A., Rupchev G.Y., Alekseyev A.A., Beniashvili A.G., Mayevskaya M.V., Poluektova Y.A., et al. Dysphoric spectrum of emotional disorders at irritable bowel syndrome. Rus J Gastroenterol Hepatol Coloproctol. 2017;27(1):12–22 (In Russ.). DOI: 10.22416/1382-4376-2017-27-1-12-22

7. Morozova M.A., Rupchev G.E., Alekseev A.A., Ulyanin A.I., Poluektova E.A., Ivashkin V.T. Latent Dysphoria in the Structure of Emotional Disorders in Patients with Functional Constipation Clinical Psychology and Special Education. 2021;10(4):68–92 (In Russ.). DOI: 10.17759/cpse.2021100404

8. Poluektova E.A., Kurbatova A.A., Rupchev G.E., Sheptulin A.A., Ivashkin V.T. Role of emotional disorders, personality features and disordersof intraceptive sensation in development of somatic symptomsat irritable bowel syndrome. Rus J Gastroenterol Hepatol Coloproctol. 2013;23(6):20–8 (In Russ.).

9. Surdea-Blaga T., Băban A., Dumitrascu D.L. Psychosocial determinants of irritable bowel syndrome. World J Gastroenterol. 2012;18(7):616–26. DOI: :10.3748/wjg.v18.i7.616

10. Ivashkin V.T., Maev I.V., Shelygin Yu.A., Baranskaya E.K., Belous S.S., Belousova E.A., et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Rus J Gastroenterol Hepatol Coloproctol. 2021;31(5):74–95 (In Russ.). DOI: 10.22416/1382-4376-2021-31-5-74-95

11. Kleinstäuber M., Witthöft M., Steffanowski A., van Marwijk H., Hiller W., Lambert M.J. Pharmacological interventions for somatoform disorders in adults. Cochrane Database Syst Rev. 2014;(11):CD010628. DOI: 10.1002/14651858.CD010628.pub2

12. Sachdeva V., Roy A., Bharadvaja N. Current Prospects of Nutraceuticals: A Review. Curr Pharm Biotechnol. 2020;21(10):884–96. DOI: :10.2174/1389201021666200130113441

13. Poluektova E.A., Beniashvili A.G., Maslennikov R.V. Nutraceuticals and Pharmaceuticals. Rus J Gastroenterol Hepatol Coloproctol. 2020;30(2):68–75 (In Russ.). DOI: 10.22416/1382-4376-2020-30-2-68-75

14. Quigley E.M., Fried M., Gwee K.A., Khalif I., Hungin A.P., Lindberg G., et al. World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: A Global Perspective Update September 2015. J Clin Gastroenterol. 2016;50(9):704–13. DOI: 10.1097/MCG.0000000000000653

15. Khanna R., MacDonald J.K., Levesque B.G. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48(6):505–12. DOI: 10.1097/MCG.0b013e3182a88357

16. Alammar N., Wang L., Saberi B., Nanavati J., Holtmann G., Shinohara R.T., et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complement Altern Med. 2019;19(1):21. DOI: 10.1186/s12906-018-2409-0

17. Amato A., Liotta R., Mulè F. Effects of menthol on circular smooth muscle of human colon: analysis of the mechanism of action. Eur J Pharmacol. 2014;740:295–301. DOI: 10.1016/j.ejphar.2014.07.018

18. Oz M., El Nebrisi E.G., Yang K.H.S., Howarth F.C., Al Kury L.T. Cellular and Molecular Targets of Menthol Actions. Front Pharmacol. 2017;8:472. DOI: 10.3389/ fphar.2017.00472

19. Luo L., Yan J., Chen B., Luo Y., Liu L., Sun Z., et al. The effect of menthol supplement diet on colitis-induced colon tumorigenesis and intestinal microbiota. Am J Transl Res. 2021;13(1):38–56.

20. Xue J., Li H., Deng X., Ma Z., Fu Q., Ma S. L-Menthone confers antidepressant-like effects in an unpredictable chronic mild stress mouse model via NLRP3 inflammasomemediated inflammatory cytokines and central neurotransmitters. Pharmacol Biochem Behav. 2015;134:42–8. DOI: 10.1016/j.pbb.2015.04.014

21. d’Alessio P.A., Ostan R., Bisson J.F., Schulzke J.D., Ursini M.V., Béné M.C. Oral administration of d-limonene controls inflammation in rat colitis and displays antiinflammatory properties as diet supplementation in humans. Life Sci. 2013;92(24–26):1151–6. DOI: 10.1016/j.lfs.2013.04.013

22. Rehman M.U., Tahir M., Khan A.Q., Khan R., OdayO-Hamiza, Lateef A., et al. D-limonene suppresses doxorubicin-induced oxidative stress and inflammation via repression of COX-2, iNOS, and NFκB in kidneys of Wistar rats. Exp Biol Med (Maywood). 2014;239(4):465–76. DOI: 10.1177/1535370213520112

23. Nikkhah Bodagh M., Maleki I., Hekmatdoost A. Ginger in gastrointestinal disorders: A systematic review of clinical trials. Food Sci Nutr. 2019;7(1):96–108. DOI: 10.1002/fsn3.807

24. Ghayur M.N., Gilani A.H. Pharmacological basis for the medicinal use of ginger in gastrointestinal disorders. Dig Dis Sci. 2005;50(10):1889–97. DOI: 10.1007/s10620-0052957-2

25. Giacosa A., Morazzoni P., Bombardelli E., Riva A., Bianchi Porro G., Rondanelli M. Can nausea and vomiting be treated with ginger extract? Eur Rev Med Pharmacol Sci. 2015;19(7):1291–6.

26. Mukonowenzou N.C., Adeshina K.A., Donaldson J., Ibrahim K.G., Usman D., Erlwanger K.H. Medicinal Plants, Phytochemicals, and Their Impacts on the Maturation of the Gastrointestinal Tract. Front Physiol. 2021;12:684464. DOI: 10.3389/fphys.2021.684464

27. Simon A., Darcsi A., Kéry Á., Riethmüller E. Bloodbrain barrier permeability study of ginger constituents. J Pharm Biomed Anal. 2020;177:112820. DOI: 10.1016/j.jpba.2019.112820

28. Nievergelt A., Huonker P., Schoop R., Altmann K.H., Gertsch J. Identification of serotonin 5-HT1A receptor partial agonists in ginger. Bioorg Med Chem. 2010;18(9):3345–51. DOI: 10.1016/j.bmc.2010.02.062

29. Ivashkin V.T., Kudryavtseva A.V., Krasnov G.S., Poluektov Yu.M., Morozova M.A., Shifrin O.S., et al. Efficacy and safety of a food supplement with standardized menthol, limonene, and gingerol content in patients with irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. PLOS ONE. 2022;17(6):e0263880. doi: 10.1371/journal.pone.0263880.

30. Ivashkin V.T., Shelygin Yu.A., Baranskaya Y.K., Belousova Y.A., Beniashvili A.G., Vasilyev S.V., et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Rus J Gastroenterol Hepatol Coloproctol. 2017;27(5):76–93 (In Russ.). DOI: 10.22416/13824376-2017-27-5-76-93

31. Ivashkin V.T., Mayev I.V., Sheptulin A.A., Lapina T.L., Trukhmanov A.S., Kartavenko I.M., et al. Diagnosis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association. Rus J Gastroenterol Hepatol Coloproctol. 2017;27(1):50–61 (In Russ.). DOI: 10.22416/1382-4376-2017-27-1-50-61

32. Ivashkin V.T, Sheptulin A.A., Poluektova E.A., Reykhart D.V, Belostotsky A.V., et al. Potential of «7×7» (7 symptoms per 7 days) questionnairein assessment of symptom dynamics of functional dyspepsia and irritable bowel syndrome. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(3):24–33 (In Russ.). DOI: 10.22416/1382-4376-2016-26-3-24-33

33. Terluin B., van Marwijk H.W., Adèr H.J., de Vet H.C., Penninx B.W., Hermens M.L., et al. The FourDimensional Symptom Questionnaire (4DSQ): a validation study of a multidimensional self-report questionnaire to assess distress, depression, anxi.ety and somatization. BMC Psychiatry. 2006;6:34. DOI: 10.1186/1471-244X6-34